Verantos featured for its RWE leadership at ISPE, DIA, and by Inc. 5000

Verantos featured for its RWE leadership at ISPE, DIA, and by Inc. 5000

As life sciences organizations have sought to better understand how to generate high-validity real-world evidence, Verantos has been on the forefront, sharing knowledge at every major industry conference. At ISPE’s 41st Annual Meeting in August, we presented a symposium on the only peer-reviewed methods to measure and optimize accuracy, completeness, and traceability. At DIA’s Global Annual Meeting in June, we presented a “how-to” on implementing traceability. At ISPOR in May, we shared a poster measuring healthcare resource utilization using high-validity methods. In October, Verantos will present at the opening session of DIA’s Real-World Evidence Conference.

Verantos was again named to the Inc. 5000's list of fastest growing private US companies, representing our fourth year in a row.

---

Company News

Verantos presents practical approaches in high-validity real-world evidence generation at ISPE’s 41st Annual Meeting

Verantos detailed practical implementation approaches to quantify and improve accuracy, completeness, and traceability consistent with peer-reviewed methods and learnings from the Verantos-led TRUST and VERIFY FDA demonstration projects.

Learn more

Verantos named to Inc. 5000 list for the fourth consecutive year

Verantos’ continued recognition on the Inc. 5000 list of the fastest-growing private companies in America reflects the importance of high-validity real-world evidence to life sciences organizations and patients.

Read the announcement

Verantos presents on traceability of RWD at DIA’s Global Annual Meeting

Verantos President Anand Shroff presented at DIA’s Global Annual Meeting along with colleagues from the US Food and Drug Administration, Amgen, Dreyer Solutions, and Mass General Brigham. He provided practical steps that included not only how to measure, but also how to use the information to detect and address errors and substantially improve data quality.

Dive into traceability

Verantos presents abstract at ISPOR 2025

Verantos presented an abstract highlighting an advanced analysis of severity progression and healthcare resource utilization in asthma.

View the research

Verantos to present at the opening session of DIA’s Real World Evidence Conference

Together with representatives from Amgen, Duke-Margolis, GSK, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency, Verantos will present at the first session at DIA RWE. The talk will highlight where the industry stands and where it needs to be in our progression toward increasingly credible RWE.

Check the agenda